Brexit: New Rules Will Hit Parallel Trade From UK to EU
Traders Disappointed At Asymmetry In IP Regimes
Executive Summary
From next year, owners of trademarks and other rights in the European Economic Area will be able to prevent the parallel export of medicines from the UK to the EEA. But those owning similar rights in the UK will not be able to stop parallel imports from EEA countries.
You may also be interested in...
EU-UK Trade Deal Allows For Mutual Recognition Of GMP Inspections
The trade deal agreed by the EU and the UK may have brought some relief to the life sciences sector in that it averts the chaos that would have followed failure to reach a deal, but it contains little that will have a direct impact on the regulation of medicines.
Industry Gets Breathing Space For Post-Brexit Regulation In Northern Ireland
The pharmaceutical industry has welcomed a decision to allow more time to bring in new medicines regulations in Northern Ireland, but continues to insist that a mutual recognition agreement between the UK and the EU on drug manufacturing is the best way forward.
COVID-19 Summit Sees Progress On Test-And-Treat, IP Licensing, & Funding Commitments
Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.